Conference Proceedings
010 Real-world experience with ocrelizumab in the MSBase registry – Australian RRMS cohort
Helmut Butzkueven, Tim Spelman, Tomas Kalincik, Katherine Buzzard, Anneke Van der Walt, Jeanette Lechner-Scott, Suzanne Hodgkinson, Ernest Butler, Richard Macdonell, Mark Slee, MSBase Study Group, Bruno Marcel
Oral abstracts | BMJ Publishing Group Ltd | Published : 2021
Abstract
Ocrelizumab (OCR) is a humanised anti-CD20+ monoclonal antibody for the treatment of Multiple Sclerosis. In Australian MSBase clinics, we describe baseline characteristics of relapsing-remitting MS (RRMS) patients treated with OCR, treatment pathways and early clinical outcomes. Secondary analysis using MSBase Registry data for RRMS patients with OCR initiation within 3 months of MSBase recorded visit. Descriptive statistics included demographics, disease course/duration, prior disease modifying therapies (DMT) and EDSS. Relapse data was described in patients with ≥6 months follow-up. As of 4 June 2020, MSBase included 624 eligible Australian RRMS patients newly treated with OCR. Median age ..
View full abstract